{"id":"NCT01064687","sponsor":"Eli Lilly and Company","briefTitle":"A Study in Participants With Type 2 Diabetes Mellitus","officialTitle":"A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-02","primaryCompletion":"2011-11","completion":"2012-05","firstPosted":"2010-02-08","resultsPosted":"2015-01-26","lastUpdate":"2015-01-26"},"enrollment":978,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"LY2189265","otherNames":["Dulaglutide"]},{"type":"DRUG","name":"Exenatide","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":[]},{"type":"DRUG","name":"Pioglitazone","otherNames":[]}],"arms":[{"label":"1.5 mg LY2189265","type":"EXPERIMENTAL"},{"label":"0.75 mg LY2189265","type":"EXPERIMENTAL"},{"label":"Exenatide","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if LY2189265 is effective and safe in reducing hemoglobin A1c (HbA1c), as compared to placebo (no medicine), or exenatide in participants with Type 2 Diabetes. The participants must also be taking metformin and pioglitazone.","primaryOutcome":{"measure":"Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)","timeFrame":"Baseline, 26 weeks","effectByArm":[{"arm":"1.5 mg LY2189265","deltaMin":-1.51,"sd":0.06},{"arm":"0.75 mg LY2189265","deltaMin":-1.3,"sd":0.06},{"arm":"Exenatide","deltaMin":-0.99,"sd":0.06},{"arm":"Placebo","deltaMin":-0.46,"sd":0.08}],"pValues":[{"comp":"OG000 vs OG003","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG003","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":20},"locations":{"siteCount":89,"countries":["United States","Argentina","Mexico","Puerto Rico"]},"refs":{"pmids":["36894938","27161178","26691396"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":280},"commonTop":["Nausea","Vomiting","Diarrhoea","Nasopharyngitis","Headache"]}}